Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 11:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 111 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Medium Protein Clear all
Completed Phase 4 Interventional Results available

Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

NCT00289536
View directory record Official record
Conditions
Hemophilia A
Interventions
Antihemophilic factor, recombinant, manufactured protein-free
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
12 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Little Rock, Arkansas • Los Angeles, California • Peoria, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 6, 2026, 11:13 PM EDT
Terminated Not applicable Interventional

Reducing Insulin, Growth Hormones, and Tumors

NCT03785808
View directory record Official record
Conditions
Diet Modification, Lung Cancer
Interventions
Special Diet Therapy (low-carb), Special Diet Therapy (low-fat), Special Diet Therapy (USDA control)
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2019 · Synced Sep 6, 2026, 11:13 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

NCT05609370
View directory record Official record
Conditions
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Interventions
Alcestobart, Tislelizumab, Bevacizumab or Bevacizumab biosimilar, Fluoropyrimidine (FP)
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
30
States / cities
Anchorage, Alaska • Gilbert, Arizona • Cerritos, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 6, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Results available

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

NCT03801902
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Accelerated Hypofractionated Radiation Therapy, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging of the Brain with and without Contrast, Monalizumab, Oleclumab, Radiation Therapy
Radiation · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
56
States / cities
Atlanta, Georgia • Augusta, Georgia • Boise, Idaho + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 6, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

NCT01681992
View directory record Official record
Conditions
Measles, Mumps, Rubella, Measles-Mumps-Rubella Vaccine
Interventions
Priorix, M-M-R II, Varivax, Havrix, Prevnar 13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
4,538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Sep 6, 2026, 11:13 PM EDT
Completed Not applicable Interventional

Nutrition for Asthmatics with Obesity

NCT05222451
View directory record Official record
Conditions
Asthma, Obesity
Interventions
DGA Diet, MCT Diet, KETO Diet
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 6, 2026, 11:13 PM EDT
Completed Phase 2Phase 3 Interventional

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

NCT03805789
View directory record Official record
Conditions
Acute-graft-versus-host Disease
Interventions
AAT, Placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
12
States / cities
Scottsdale, Arizona • St. Petersburg, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 6, 2026, 11:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.

NCT00784719
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
CP-690,550, Cyclosporine, CP-690,550 Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
Chandler, Arizona • Peoria, Arizona • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Sep 6, 2026, 11:13 PM EDT
Completed Not applicable Interventional

Multi-Media Parent-based Intervention to Promote Dental Hygiene Among Young Children: BeReady2Smile

NCT03637309
View directory record Official record
Conditions
Dental Caries in Children
Interventions
BeReady2Smile Video and App
Behavioral
Lead sponsor
Oregon Research Behavioral Intervention Strategies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 6, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Women's Isoflavone Soy Health (WISH) Trial

NCT00118846
View directory record Official record
Conditions
Atherosclerosis
Interventions
25 gm soy protein supplement, Placebo
Dietary Supplement · Other
Lead sponsor
University of Southern California
Other
Eligibility
30 Years and older · Female only
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 6, 2026, 11:13 PM EDT
Completed Phase 4 Interventional

Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease

NCT02476526
View directory record Official record
Conditions
Chronic Kidney Disease, Pulmonary Embolism, Renal Artery Stenosis, Pulmonary Cancer
Interventions
Low Volume iso-osmolar non-ionic radio contrast medium, Acetylcysteine Inhalation, Sodium Bicarbonate Solution, 64-MDCT Scanning
Drug · Procedure
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2017 · Synced Sep 6, 2026, 11:13 PM EDT
Recruiting No phase listed Observational

Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.

NCT06252493
View directory record Official record
Conditions
Crohn Disease
Interventions
Radiotracer Injection, Contrast Media, Magnetic Resonance, Blood Draw, Glucagon, Imaging, Oral contrast media application
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 6, 2026, 11:13 PM EDT
Active, not recruiting Phase 2 Interventional

A Trial of Vigil for Participants With Ovarian Cancer

NCT02346747
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Neoplasms
Interventions
Vigil, Placebo
Biological · Other
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
26
States / cities
Mobile, Alabama • Irvine, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 6, 2026, 11:13 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Determine How Consumption of Dairy Fat as Cheese Influences Inflammation-Phase 2

NCT01803633
View directory record Official record
Conditions
Metabolic Syndrome, Obesity
Interventions
Cheddar cheese, Vegan cheese
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2027
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 6, 2026, 11:13 PM EDT
Completed Phase 3 Interventional

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

NCT00324727
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer
Interventions
melphalan, regional chemotherapy, systemic chemotherapy, hepatic artery embolization
Drug · Procedure
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
18 Years to 120 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
12
States / cities
Santa Monica, California • Englewood, Colorado • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Sep 6, 2026, 11:13 PM EDT
Active, not recruiting Not applicable Interventional

Targeting Human Milk Fortification to Improve Preterm Infant Growth and Brain Development

NCT03977259
View directory record Official record
Conditions
Preterm Birth, Breast Milk Expression, Nutrition Disorder, Infant, Brain Development Abnormality, Neurodevelopmental Disorders
Interventions
Individually targeted fortification
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
1 Day to 21 Days
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 6, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure

NCT00435162
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan 0.25 mg/kg, Valsartan 1.0 mg/kg, Valsartan 4.0 mg/kg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Months to 5 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
USA, New Jersey
Source: ClinicalTrials.gov public record
Updated May 8, 2011 · Synced Sep 6, 2026, 11:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of MetAP2 Inhibition on Bioenergetics and Aging-associated Characteristics in Adipose Tissue in Healthy Participants

NCT05989035
View directory record Official record
Conditions
Aging
Interventions
Abdominal subcutaneous adipose tissue biopsy
Procedure
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 6, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Results available

Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer

NCT01090011
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cetuximab, BIBW 2992
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Aurora, Colorado • New Haven, Connecticut • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Sep 6, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab

NCT00826267
View directory record Official record
Conditions
Breast Neoplasms
Interventions
lapatinib, BIBW 2992, trastuzumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 30, 2013 · Synced Sep 6, 2026, 11:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Protein Requirement of Elderly Men and Women

NCT00812500
View directory record Official record
Conditions
Age
Interventions
Lower Protein, Medium Protein, Higher Protein
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Sep 6, 2026, 11:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Return of First-phase Insulin Secretion in Type 2 Diabetes is Associated With Depletion of Pancreas Lipid

NCT03430310
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Low Glycemic Diet, Control Diet
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
35 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 6, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

NCT00084656
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
ipilimumab, Tyrosinase/gp100/MART-1 Peptides
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 120 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 6, 2026, 11:13 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

NCT06965413
View directory record Official record
Conditions
Obesity, Overweight, Overweight With One Weight Related Comorbidity
Interventions
RO7204239, RO7204239 Matching Placebo, Tirzepatide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Anniston, Alabama • Spring Valley, California • Clermont, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 6, 2026, 11:13 PM EDT